GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Baijin Life Science Holdings Ltd (OTCPK:MNNGF) » Definitions » Net Income

MNNGF (Baijin Life Science Holdings) Net Income : $-1.46 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Baijin Life Science Holdings Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Baijin Life Science Holdings's Net Income for the six months ended in Sep. 2024 was $-0.80 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.46 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Baijin Life Science Holdings's Earnings per Share (Diluted) for the six months ended in Sep. 2024 was $-0.00.


Baijin Life Science Holdings Net Income Historical Data

The historical data trend for Baijin Life Science Holdings's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baijin Life Science Holdings Net Income Chart

Baijin Life Science Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.29 -6.67 -1.98 1.11 -0.95

Baijin Life Science Holdings Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.31 -0.20 -0.30 -0.66 -0.80

Baijin Life Science Holdings Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Baijin Life Science Holdings's Net Income for the fiscal year that ended in Mar. 2024 is calculated as

Net Income(A: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.09+-0.002+0+0.14
=-0.95

Baijin Life Science Holdings's Net Income for the quarter that ended in Sep. 2024 is calculated as

Net Income(Q: Sep. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=0.091+-0.335+0+-0.555
=-0.80

Net Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baijin Life Science Holdings  (OTCPK:MNNGF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Baijin Life Science Holdings's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Baijin Life Science Holdings Net Income Related Terms

Thank you for viewing the detailed overview of Baijin Life Science Holdings's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Baijin Life Science Holdings Business Description

Traded in Other Exchanges
Address
66 Gloucester Road, Office B, 9/F Pico Tower, Wanchai, Hong Kong, HKG
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company produces health products that are affordable for the general public. The business segments of the company are Life Science segment which includes cellular technology-based services, provide including cellular drugs R&D, large molecule drugs R&D, clinical research services and R&D and sales on self-owned skincare brand, and Fine Jewelry segment that focuses on the procurement, processing, design, production and wholesale distribution of pearls and fine jewelry products.

Baijin Life Science Holdings Headlines